Articles published by Business Wire
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
Today 2:00 EDT
From Iksuda Therapeutics
Via Business Wire
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Today 1:05 EDT
From Natera, Inc.
Via Business Wire
Tickers
NTRA
From AM Best
Via Business Wire
From Genentech
Via Business Wire
Tickers
RHHBY
From AM Best
Via Business Wire
AM Best to Host Market Briefing at 2025 Singapore International Reinsurance Conference
October 19, 2025
From AM Best
Via Business Wire
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
October 19, 2025
Via Business Wire
Tickers
LHX
F5, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FFIV
October 19, 2025
From The DJS Law Group
Via Business Wire
Tickers
FFIV
FFIV Investors Have Opportunity to Join F5, Inc. Fraud Investigation with the Schall Law Firm
October 19, 2025
From The Schall Law Firm
Via Business Wire
Tickers
FFIV
FRPT Investors Have Opportunity to Join Freshpet, Inc. Fraud Investigation with the Schall Law Firm
October 19, 2025
From The Schall Law Firm
Via Business Wire
Tickers
FRPT
From Citi
Via Business Wire
Tickers
C
From Summit Therapeutics
Via Business Wire
Tickers
SMMT
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
October 19, 2025
Via Business Wire
Tickers
GILD
From AstraZeneca
Via Business Wire
Tickers
AZN
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
October 19, 2025
From Pfizer Inc.
Via Business Wire
Tickers
PFE
From Daiichi Sankyo
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.